The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab

Elena Cittera, Marzia Leidi, Chiara Buracchi, Fabio Pasqualini, Silvano Sozzani, Annunciata Vecchi, J. Douglas Waterfield, Martino Introna, Josée Golay

Research output: Contribution to journalArticle

Abstract

The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB following binding to the CD20 Ag. Induction of CCL3/4 in vitro was specific, was observed in several cell lines and freshly isolated lymphoma samples and also took place at the protein level in vitro and in vivo. To investigate the role of these β-chemokines in the mechanism of action of rituximab, we synthesized a N-terminally truncated CCL3 molecule CCL3(11-70), which had antagonist activity on chemotaxis mediated by either CCL3 or BJAB supernatant. We also set up an established s.c. BJAB tumor model in athymic mice. Rituximab, given weekly after tumors had reached 250 mm2, led to complete disappearance of the lymphoma within 2-3 wk. Treatment of mice with cobra venom factor showed that complement was required for rituximab therapeutic activity. Treatment of BJAB tumor bearing mice every 2 days with the CCL3(11-70) antagonist, starting 1 wk before rituximab treatment, had no effect on tumor growth by itself, but completely inhibited the therapeutic activity of the Ab. To determine whether CCL3 acts through recruitment/activation of immune cells, we specifically depleted NK cells, polymorphonuclear cells, and macrophages using mAbs, clodronate treatment, or Rag2_/-_/_ mice. The data demonstrated that these different cell populations are involved in BJAB tumor eradication. We propose that rituximab rapidly activates complement and induces β-chemokines in vivo, which in turn activate the innate immunity network required for efficient eradication of the bulky BJAB tumor.

Original languageEnglish
Pages (from-to)6616-6623
Number of pages8
JournalJournal of Immunology
Volume178
Issue number10
Publication statusPublished - May 15 2007

Fingerprint

Chemokine CCL3
Heterografts
Innate Immunity
Lymphoma
Neoplasms
Chemokines
Therapeutics
Chemokine CCL4
Clodronic Acid
Chemotaxis
Rituximab
Nude Mice
Natural Killer Cells
Macrophages
Cell Line
Growth

ASJC Scopus subject areas

  • Immunology

Cite this

The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. / Cittera, Elena; Leidi, Marzia; Buracchi, Chiara; Pasqualini, Fabio; Sozzani, Silvano; Vecchi, Annunciata; Waterfield, J. Douglas; Introna, Martino; Golay, Josée.

In: Journal of Immunology, Vol. 178, No. 10, 15.05.2007, p. 6616-6623.

Research output: Contribution to journalArticle

Cittera, E, Leidi, M, Buracchi, C, Pasqualini, F, Sozzani, S, Vecchi, A, Waterfield, JD, Introna, M & Golay, J 2007, 'The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab', Journal of Immunology, vol. 178, no. 10, pp. 6616-6623.
Cittera, Elena ; Leidi, Marzia ; Buracchi, Chiara ; Pasqualini, Fabio ; Sozzani, Silvano ; Vecchi, Annunciata ; Waterfield, J. Douglas ; Introna, Martino ; Golay, Josée. / The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. In: Journal of Immunology. 2007 ; Vol. 178, No. 10. pp. 6616-6623.
@article{7195d7a4541f4c8e8cc991c6843c26af,
title = "The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab",
abstract = "The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB following binding to the CD20 Ag. Induction of CCL3/4 in vitro was specific, was observed in several cell lines and freshly isolated lymphoma samples and also took place at the protein level in vitro and in vivo. To investigate the role of these β-chemokines in the mechanism of action of rituximab, we synthesized a N-terminally truncated CCL3 molecule CCL3(11-70), which had antagonist activity on chemotaxis mediated by either CCL3 or BJAB supernatant. We also set up an established s.c. BJAB tumor model in athymic mice. Rituximab, given weekly after tumors had reached 250 mm2, led to complete disappearance of the lymphoma within 2-3 wk. Treatment of mice with cobra venom factor showed that complement was required for rituximab therapeutic activity. Treatment of BJAB tumor bearing mice every 2 days with the CCL3(11-70) antagonist, starting 1 wk before rituximab treatment, had no effect on tumor growth by itself, but completely inhibited the therapeutic activity of the Ab. To determine whether CCL3 acts through recruitment/activation of immune cells, we specifically depleted NK cells, polymorphonuclear cells, and macrophages using mAbs, clodronate treatment, or Rag2_/-cγ_/_ mice. The data demonstrated that these different cell populations are involved in BJAB tumor eradication. We propose that rituximab rapidly activates complement and induces β-chemokines in vivo, which in turn activate the innate immunity network required for efficient eradication of the bulky BJAB tumor.",
author = "Elena Cittera and Marzia Leidi and Chiara Buracchi and Fabio Pasqualini and Silvano Sozzani and Annunciata Vecchi and Waterfield, {J. Douglas} and Martino Introna and Jos{\'e}e Golay",
year = "2007",
month = "5",
day = "15",
language = "English",
volume = "178",
pages = "6616--6623",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab

AU - Cittera, Elena

AU - Leidi, Marzia

AU - Buracchi, Chiara

AU - Pasqualini, Fabio

AU - Sozzani, Silvano

AU - Vecchi, Annunciata

AU - Waterfield, J. Douglas

AU - Introna, Martino

AU - Golay, Josée

PY - 2007/5/15

Y1 - 2007/5/15

N2 - The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB following binding to the CD20 Ag. Induction of CCL3/4 in vitro was specific, was observed in several cell lines and freshly isolated lymphoma samples and also took place at the protein level in vitro and in vivo. To investigate the role of these β-chemokines in the mechanism of action of rituximab, we synthesized a N-terminally truncated CCL3 molecule CCL3(11-70), which had antagonist activity on chemotaxis mediated by either CCL3 or BJAB supernatant. We also set up an established s.c. BJAB tumor model in athymic mice. Rituximab, given weekly after tumors had reached 250 mm2, led to complete disappearance of the lymphoma within 2-3 wk. Treatment of mice with cobra venom factor showed that complement was required for rituximab therapeutic activity. Treatment of BJAB tumor bearing mice every 2 days with the CCL3(11-70) antagonist, starting 1 wk before rituximab treatment, had no effect on tumor growth by itself, but completely inhibited the therapeutic activity of the Ab. To determine whether CCL3 acts through recruitment/activation of immune cells, we specifically depleted NK cells, polymorphonuclear cells, and macrophages using mAbs, clodronate treatment, or Rag2_/-cγ_/_ mice. The data demonstrated that these different cell populations are involved in BJAB tumor eradication. We propose that rituximab rapidly activates complement and induces β-chemokines in vivo, which in turn activate the innate immunity network required for efficient eradication of the bulky BJAB tumor.

AB - The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB following binding to the CD20 Ag. Induction of CCL3/4 in vitro was specific, was observed in several cell lines and freshly isolated lymphoma samples and also took place at the protein level in vitro and in vivo. To investigate the role of these β-chemokines in the mechanism of action of rituximab, we synthesized a N-terminally truncated CCL3 molecule CCL3(11-70), which had antagonist activity on chemotaxis mediated by either CCL3 or BJAB supernatant. We also set up an established s.c. BJAB tumor model in athymic mice. Rituximab, given weekly after tumors had reached 250 mm2, led to complete disappearance of the lymphoma within 2-3 wk. Treatment of mice with cobra venom factor showed that complement was required for rituximab therapeutic activity. Treatment of BJAB tumor bearing mice every 2 days with the CCL3(11-70) antagonist, starting 1 wk before rituximab treatment, had no effect on tumor growth by itself, but completely inhibited the therapeutic activity of the Ab. To determine whether CCL3 acts through recruitment/activation of immune cells, we specifically depleted NK cells, polymorphonuclear cells, and macrophages using mAbs, clodronate treatment, or Rag2_/-cγ_/_ mice. The data demonstrated that these different cell populations are involved in BJAB tumor eradication. We propose that rituximab rapidly activates complement and induces β-chemokines in vivo, which in turn activate the innate immunity network required for efficient eradication of the bulky BJAB tumor.

UR - http://www.scopus.com/inward/record.url?scp=34248224220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248224220&partnerID=8YFLogxK

M3 - Article

C2 - 17475893

AN - SCOPUS:34248224220

VL - 178

SP - 6616

EP - 6623

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -